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BETWEEN September 10, 1995, and September 20, 1997, 
a total of 208 adult patients undergoing their first or second 
cadaveric renal transplantation alone were randomized to 
receive tacrolimus!prednisone (n = 106) or tacrolimus/pred-
nisone/mycophenolate mofetil (n = 102), without induction 
antilymphocyte antibody therapy. The mean recipient age was 
50.8 ::!:: 13.7 years (range 19 to 84). Thirty-one (14.9%) patients 
were undergoing their second transplant, and 11 (5.3%) had a 
panel-reactive antibody level of over 40%. Sixty-three (30.3%) 
patients were 60 years of age or older at the time of transplan-
tation, and 16 (7.7%) patients had undergone previous liver or 
heart transplantation. The mean donor age was 34.5 ::!:: 21.7 
years (range 0.01 to 76.5). Twenty-eight (13.5%) donors were 
60 years of age or older, and 25 (12.0%) donors were 3 years 
of age or younger, and were transplanted en bloc. The mean 
cold ischemia time was 30.5 ::!:: 9.2 hours (range 4.7 to 57.!). 
The mean number of HLA matches and mismatches was 
2.5 ::!:: 1.4 and 3.1 ::!:: 1.5, respectively. There were 17 (8.2%) 0 
antigen mismatches. The mean follow-up was 15 ::!:: 17 months. 
The data were analyzed by intention-to-treat. The overall 
I-year actuarial patient survival was 94%; in the double 
therapy group, it was 93%, and in the triple therapy group, 
it was 96%. Overall I-year actuarial graft survival was 87%; 
in the double therapy group, it was 85%, and in the triple 
therapy group, it was 89%. When the patient and graft survival 
data were stratified to recipients under the age of 60 who did 
not have delayed graft function, the overall I-year actuarial 
patient survival was 97%, 95% in the double therapy group, 
and 98% in the triple therapy group. The corresponding 
l-year actuarial graft survival was 93%,92% in the double 
therapy group, and 93% in the triple therapy group. 
The mean serum creatinine was 1.6 ::!:: 0.8 mg/dL, 1.6 ::!:: 
0.9 mg/dL in the double therapy group and 1.7 ::!:: 0.7 mg/dL 
in the triple therapy group. The mean tacrolimus dose was 
8.7 ::!:: 6.6 mg/d; in the double therapy group it was 8.4 ::!:: 6.0 
mg/d, and in the triple therapy group, it was 9.0 ::!:: 7.1 mg/d. 
The mean tacrolimus level was 10.1 ::!:: 4.4 ng/mL; in the 
double therapy group, it was 10.2 ::!:: 4.5 ng/mL, while in the 
triple therapy group, it was 10.1 ::!:: 4.2 ng/mL. The mean MMF 
dose in the patients taking MMF was 1142 ::!:: 493 mg/d. 
Thirty-six percent of the successfully transplanted pa-
tients were taken off prednisone. 34% in the double therapy 
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group and 39% in the triple therapy group; 32% of the 
patients were taken off antihypertensive medications, 25% 
in the double therapy group and 39% in the triple therapy 
group. Then mean serum cholesterol level was 196 ::!:: 55 
mg/dL, and was 200 ::!:: 62 mg/dL in the double therapy 
group, and 192 ::!:: 46 mg/dL in the triple therapy group. 
Overall incidence of rejection was 36%; in the double 
therapy group, it was 44%, while in the triple therapy group. 
it was 27% (P < .012). In the triple therapy patients who 
never came off MMF, the incidence of rejection was 16%, 
while in those discontinuing MMF, it was 49%. In addition, 
there was a trend toward more severe rejections in the double 
therapy group. The overall incidence of steroid-resistant re-
jection was 5.3%; in the double therapy group, it was 7.5%, 
whereas in the triple therapy group, it was 2.9%. The inci-
dence of delayed graft function was 21 %, 21 % in the double 
therapy group, and 21 % in the triple therapy group. Incidence 
of cytomegalovirus was 12.5%, 8.5% in the double therapy 
group and 16.7% in the triple therapy group (P = NS). The 
initial and final incidences of posttransplant diabetes mellitus 
were, respectively, 7.0% and 2.9%, 9.3% and 4.7% in the 
double therapy group, and 4.7% and 1.2% in the triple therapy 
group. The overall incidence of crossover was 31%,28% from 
double to triple therapy, and 34% from triple therapy to 
double therapy; in the second year of the trial, the incidence of 
crossover from triple to double therapy decreased to 12%. 
These data suggest that the combination of tacrolimus, 
mycophenolate, and prednisone is associated with a lower 
incidence of rejection than the combination of tacrolimus 
and steroids, although there is no difference in patient or 
graft survival at 1 year. There are side effects associated with 
triple therapy, but they have been generally manageable with 
dosage reduction. Finally, this trial suggests that the combina-
tion of tacrolimus and MMF is associated with excellent 
patient and graft survival, and a low incidence of rejection. 
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